Pluristem Therapeutics Inc (PSTI)

[FDApproved]

“We’re planning to reveal the first product towards Q3 this year. It will be a whole cut type product, not nuggets or processed burgers.”

Ever After’s plants will require ‘significantly lower capital expenditures and lower production costs’
Rather than proliferating cells in large stir tank bioreactors, which Rosenthal argues are expensive and provide diminishing returns once you get above a certain size, Ever After deploys a two-stage approach in smaller packed bed vessels, and is planning a pilot facility in Israel next year.

First, cells grow on non-edible carriers, from which they are detached using mechanical force (patented vibrations technology). They are then transferred to production bioreactors where they seed onto edible scaffolding and differentiate and mature into meaty tissue.

According to Rosenthal, Ever After’s plants will require “significantly lower capital expenditures and [operate at] lower production costs, providing a 700% increase in productivity compared to other cultivated meat technology platforms. We can produce more than 10 kilos of cultivated meat mass with just a 35-liter production bioreactor and have a proven path to scale and reach price parity.”

He added: “An Ever After 1,400-liter bioreactor can produce 400 kilos of cultivated meat, whereas using competing technologies, you’d need a 10,000+-liter bioreactor to produce an equivalent amount. We have a huge cost advantage.”

We’re also recycling our serum-free media, which allows us to reduce costs dramatically. Our system is very compact, so the total volume of the system is lower and more cost-effective in terms of media and supplements both for cell growth and differentiation.”

We’re planning to reveal the first product towards Q3 this year. It will be a whole cut type product, not nuggets or processed burgers.”

Down the road, however, Ever After hopes to serve as a technology enabler for the wider industry, he said: “We are looking to license our bioreactor technology.”

As for funding, he said, “We have [enough] money for the next two years.”

Asked about regulatory approvals, he said: “We’re in ongoing discussions in Israel and the US, where what regulators are looking for is much clearer with the approval for UPSIDE Foods,” which recently received a ‘no questions’ letter from the US Food and Drug Administration affirming the safety of its process for cultivated chicken, he said.

https://agfundernews.com/ever-after-foods-addresses-critical-scaling-challenge-in-cultivated-meat